Published in Thromb Haemost on October 29, 1982
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet (1990) 6.54
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med (1995) 4.32
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost (2005) 3.47
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 2.53
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med (1996) 2.51
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med (1997) 2.41
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol (1998) 2.18
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol (2003) 2.16
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol (2000) 2.09
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia (2007) 2.09
A multicenter study of treatment of primary CNS lymphoma. Neurology (2002) 2.04
Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood (1990) 2.04
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia (2013) 1.97
Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost (1993) 1.65
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia (2010) 1.63
Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost (1991) 1.55
Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet (1992) 1.54
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia (2006) 1.51
Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood (1998) 1.49
Healthcare costs of multiple myeloma: an Italian study. Eur J Cancer Care (Engl) (2011) 1.47
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol (1990) 1.42
Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol (1993) 1.42
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J Clin Oncol (1995) 1.42
The treatment of polycythaemia vera: an update in the JAK2 era. Intern Emerg Med (2007) 1.40
Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Cancer (1992) 1.39
Increased levels of beta 2-glycoprotein I (aca-Cofactor) in patients with lupus anticoagulant. Thromb Haemost (1992) 1.39
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia (2007) 1.35
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood (2000) 1.34
Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther (2000) 1.34
Bacterial endocarditis produced by Listeria monocytogenes. Case presentation and review of literature. Am J Clin Pathol (1975) 1.29
High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood (1991) 1.25
Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation (2000) 1.24
Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG) Ann Oncol (1999) 1.24
Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol (2004) 1.22
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol (2001) 1.20
Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood (1999) 1.17
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia (2008) 1.15
Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer (1990) 1.15
Factor VIII-related properties in platelets from patients with von Willebrand's disease. J Lab Clin Med (1978) 1.12
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol (2006) 1.09
What are RBC-transfusion-dependence and -independence? Leuk Res (2010) 1.09
Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood (1989) 1.08
Subunits A and S inheritance in four families with congenital factor XIII deficiency. Br J Haematol (1978) 1.08
Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol (2000) 1.07
T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells. J Exp Med (1985) 1.07
Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol (1999) 1.07
Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood (1997) 1.04
Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology (1991) 1.03
Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost (1997) 1.02
Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. J Clin Oncol (1989) 1.02
Trends in mortality from leukemia in subsequent age groups. Leukemia (2000) 1.02
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia (2011) 1.00
Thrombocytopenia in the antiphospholipid syndrome. Br J Haematol (1996) 1.00
All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. Br J Haematol (1996) 0.98
Molecular subunits and transamidase activity of factor XIII during disseminated intravascular coagulation in acute leukaemia. Thromb Haemost (1980) 0.97
Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia (2003) 0.97
AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. Blood (1996) 0.96
Further characterization of platelet-aggregating cysteine proteinase activity in thrombotic thrombocytopenic purpura. Br J Haematol (1994) 0.96
Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia (1999) 0.95
A new procoagulant in acute leukemia. Blood (1988) 0.95
Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood (1989) 0.94
Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost (1992) 0.94
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol (1991) 0.93
Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood (1984) 0.93
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia (2013) 0.92
Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med (1994) 0.92
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb Haemost (1998) 0.90
Hereditary dysfunctional protein C (protein C Bergamo) and thrombosis. Lancet (1984) 0.90
Antiphospholipid antibodies and recurrent abortion. Obstet Gynecol (1991) 0.90
Association of NK-cell lymphoproliferative disease and nephrotic syndrome. Am J Clin Pathol (1990) 0.89
Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. J Clin Oncol (1989) 0.89
Is female sex an independent predictor of in-hospital mortality in acute myocardial infarction? Arq Bras Cardiol (2001) 0.89
Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood (1999) 0.89
Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? Leukemia (2011) 0.88
Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood (1998) 0.88
Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost (1996) 0.88
Nosocomial outbreak of severe Pseudomonas aeruginosa infections in haematological patients. Eur J Epidemiol (1993) 0.88
Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost (1994) 0.87
Autoimmunity and B-cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells. Cancer (1989) 0.87